John F. Thompson, PhD

Nabsys, Rhode Island, United States

John Thompson received degrees in chemistry from Yale (BS) and the University of California, Berkeley (PhD). He has applied that knowledge across a variety of companies in efforts to improve human health. This work has spanned both biotech and pharma, developing drugs while at Pfizer (small molecules) and Homology Medicines (AAV-based gene therapies). Genomics companies have included those developing leading edge instrumentation (Helicos and Nabsys), as well as the use of NGS-based genetic testing/diagnostics for pediatric Mendelian diseases (Claritas) and cancer detection (PGDx). His current focus is on improving genome-wide structural variant analysis using electronic detection of ultra-long DNA molecules in nanochannels to better understand genetic diseases and cancer.

Disclosure information not submitted.

Presentation(s):

• Electronic Detection of ultra-long DNA molecules in Nanochannels to Identify Structural Variants at High Resolution

  Monday, February 5, 2024
  3:30 PM – 4:00 PM EST